Stock DNA
Pharmaceuticals & Biotechnology
USD 249 Million (Micro Cap)
NA (Loss Making)
NA
0.00%
0.17
-34.15%
4.50
Revenue and Profits:
Net Sales:
52 Million
(Quarterly Results - Jun 2025)
Net Profit:
-6 Million
Total Returns (Price + Dividend) 
TimePeriod
Price Return
Dividend Return
Total Return
3 Months
28.75%
0%
28.75%
6 Months
53.73%
0%
53.73%
1 Year
30.38%
0%
30.38%
2 Years
-8.44%
0%
-8.44%
3 Years
-44.47%
0%
-44.47%
4 Years
-70.36%
0%
-70.36%
5 Years
-74.79%
0%
-74.79%
Cerus Corp. for the last several years.
Risk Adjusted Returns v/s 
News
No Recent News for the Company
Announcements 
No announcement available
Corporate Actions 
No corporate action available
Quality key factors 
Factor
Value
Sales Growth (5y)
17.87%
EBIT Growth (5y)
9.20%
EBIT to Interest (avg)
-11.00
Debt to EBITDA (avg)
Negative Net Debt
Net Debt to Equity (avg)
0.12
Sales to Capital Employed (avg)
1.24
Tax Ratio
1.09%
Dividend Payout Ratio
0
Pledged Shares
0
Institutional Holding
83.59%
ROCE (avg)
0
ROE (avg)
0
Valuation key factors
Factor
Value
P/E Ratio
NA (Loss Making)
Industry P/E
Price to Book Value
5.20
EV to EBIT
-8.75
EV to EBITDA
-9.39
EV to Capital Employed
4.76
EV to Sales
1.59
PEG Ratio
NA
Dividend Yield
NA
ROCE (Latest)
-54.34%
ROE (Latest)
-34.22%
Technicals key factors
Indicator
Weekly
Monthly
MACD
Bullish
Mildly Bullish
RSI
Bearish
No Signal
Bollinger Bands
Mildly Bullish
Bullish
Moving Averages
Bullish (Daily)
KST
Bullish
Mildly Bullish
Dow Theory
No Trend
Mildly Bullish
OBV
No Trend
Mildly Bullish
Shareholding Snapshot : Mar 2025
Shareholding Compare (%holding) 
Majority shareholders
Domestic Funds
Domestic Funds
Held in 36 Schemes (33.52%)
Foreign Institutions
Held by 71 Foreign Institutions (9.41%)
Strategic Entities with highest holding
Highest Public shareholder
Quarterly Results Snapshot (Consolidated) - Jun'25 - YoY
Jun'25
Jun'24
Change(%)
Net Sales
52.40
45.10
16.19%
Operating Profit (PBDIT) excl Other Income
-10.80
-8.80
-22.73%
Interest
2.10
2.30
-8.70%
Exceptional Items
0.00
0.00
Consolidate Net Profit
-5.70
-5.80
1.72%
Operating Profit Margin (Excl OI)
-211.80%
-205.80%
-0.60%
USD in Million.
Net Sales
YoY Growth in quarter ended Jun 2025 is 16.19% vs 15.94% in Jun 2024
Consolidated Net Profit
YoY Growth in quarter ended Jun 2025 is 1.72% vs 56.39% in Jun 2024
Annual Results Snapshot (Consolidated) - Dec'24
Dec'24
Dec'23
Change(%)
Net Sales
180.30
156.40
15.28%
Operating Profit (PBDIT) excl Other Income
-33.30
-54.40
38.79%
Interest
8.90
8.40
5.95%
Exceptional Items
0.00
-3.70
100.00%
Consolidate Net Profit
-21.00
-37.60
44.15%
Operating Profit Margin (Excl OI)
-195.70%
-363.00%
16.73%
USD in Million.
Net Sales
YoY Growth in year ended Dec 2024 is 15.28% vs -3.46% in Dec 2023
Consolidated Net Profit
YoY Growth in year ended Dec 2024 is 44.15% vs 12.15% in Dec 2023
About Cerus Corp. 
Cerus Corp.
Pharmaceuticals & Biotechnology
Cerus Corporation is a biomedical products company. The Company is engaged in developing and commercializing the INTERCEPT Blood System for blood safety. The Company operates through blood safety segment. The Company's INTERCEPT Blood System is based on its technology for controlling biological replication, and is designed to reduce blood-borne pathogens in donated blood components intended for transfusion. The Company's INTERCEPT Blood System is designed to target and inactivate blood-borne pathogens, such as viruses, including human immunodeficiency virus (HIV), West Nile, Severe acute respiratory syndrome (SARS), hepatitis B and C; bacteria and parasites, as well as harmful white blood cells, while preserving the therapeutic properties of platelet, plasma and red blood cell transfusion products. The Company's INTERCEPT Blood System is for use with blood components, including plasma, platelets, and red blood cells.
Company Coordinates 
Company Details
1220 Concord Ave Ste 600 , CONCORD CA : 94520-4906
Registrar Details






